Orion Oyj (ORINF) versus Its Rivals Head-To-Head Review

Profitability

This table compares Orion Oyj and its peers’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Orion Oyj	N/A	N/A	N/A
Orion Oyj Competitors	-2,505.37%	-250.75%	-16.90%

Dividends

Orion Oyj pays an annual dividend of $1.25 per share and has a dividend yield of 1.5%. Orion Oyj pays out 77.8% of its earnings in the form of a dividend, suggesting it may not have sufficient earnings to cover its dividend payment in the future. As a group, “Pharmaceuticals” companies pay a dividend yield of 3.7% and pay out 48.3% of their earnings in the form of a dividend. Orion Oyj lags its peers as a dividend stock, given its lower dividend yield and higher payout ratio.

Institutional & Insider Ownership

18.8% of Orion Oyj shares are owned by institutional investors. Comparatively, 32.8% of shares of all “Pharmaceuticals” companies are owned by institutional investors. 14.1% of shares of all “Pharmaceuticals” companies are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Earnings and Valuation

This table compares Orion Oyj and its peers top-line revenue, earnings per share and valuation.

	Gross Revenue	Net Income	Price/Earnings Ratio
Orion Oyj	N/A	N/A	51.50
Orion Oyj Competitors	$3.52 billion	$3.11 billion	540.27

Orion Oyj’s peers have higher revenue and earnings than Orion Oyj. Orion Oyj is trading at a lower price-to-earnings ratio than its peers, indicating that it is currently more affordable than other companies in its industry.

Summary

Orion Oyj peers beat Orion Oyj on 6 of the 9 factors compared.

Orion Oyj Company Profile

Orion Oyj develops, manufactures, and markets human and veterinary pharmaceuticals and active pharmaceutical ingredients (APIs) in Finland, Scandinavia, rest of Europe, North America, and internationally. The company provides prescription drugs and self-care products, which includes Nubeqa for the treatment of prostate cancer; Precedex, Dexdor, and Precedex for human use; Burana for inflammatory pain; Divina series for menopausal symptoms; Trexan for rheumatoid arthritis and cancer; Stalevo, Entacapone, and Comtess/Comtan for Parkinson’s disease; Biosimilars for rheumatoid arthritis and inflammatory bowel diseases; and Simdax for acute decompensated heart failure, as well as Fareston for breast cancer. It also offers Salmeterol/fluticasone Easyhaler, Budesonide/formoterol Easyhaler, Formoterol Easyhaler, Budesonide Easyhaler, Beclomet Easyhaler, and Buventol Easyhaler drugs for the treatment of asthma and chronic obstructive pulmonary disease. In addition, the company provides veterinary drugs comprising Bonqat, Clevor, Domosedan, Domitor, Antisedan, Dexdomitor, Domosedan Gel, Sileo, and Tessie; APIs for generic compounds and proprietary products, as well as contract manufacturing services; and markets and sells veterinary drugs manufactured by other international companies. Further, the company has partnership with Propeller Health to connect the Easyhaler(R) product portfolio; and a research collaboration and license agreement with Amneal Pharmaceuticals, Inc. to commercialize Amneal’s generic products. Orion Oyj was founded in 1917 and is headquartered in Espoo, Finland.